WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Given the clinical demand for WT1-driven advanced CML therapy, as well as the ongoing challenges of delivering therapeutic peptides to the nuclei of tumor cells in vivo, we have designed a potential strategy for refractory CML therapy, which involves the encapsulation of a TAT-mediated nucleus-targeting WT1 antagonistic peptide with PEG-PE.